-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Melanoma Drug Details: RP-1 is under development for...
-
Product Insights
NewNon-infectious Uveitis – Drugs In Development, 2024
Empower your strategies with our Non-infectious Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. Noninfectious uveitis can result from an eye injury or a disease somewhere else in your body. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve...
-
Product Insights
NewPosterior Uveitis – Drugs In Development, 2024
Empower your strategies with our Posterior Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Posterior uveitis refers to intraocular inflammation in the vitreous, retina, or choroid. Chorioretinitis is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. It is a form of posterior uveitis. Inflammation of these layers can lead to vision-threatening complications. The Posterior Uveitis drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewAnterior Uveitis – Drugs In Development, 2024
Empower your strategies with our Anterior Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Inflammation of the eyes is known as Uveitis. If inflammation occurs at the anterior portion of the eye (iris) it is known as anterior uveitis. Uveitis damages the uvea, the middle layer of the eye consisting of the iris, ciliary body, and choroid. Common causes are any trauma to the eye, underlying health issues like diabetes, viral infections HSV, syphilis, TB, and...
-
Product Insights
NewOptic Neuritis – Drugs In Development, 2024
Empower your strategies with our Optic Neuritis – Drugs In Development, 2024 report and make more profitable business decisions. Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon, and flashing lights. Risk factors include age and genetic mutations. The Optic Neuritis drugs in development market research report provide comprehensive information on the therapeutics under development for Optic Neuritis,...
-
Product Insights
NewIntermediate Uveitis – Drugs In Development, 2024
Empower your strategies with our Intermediate Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Intermediate uveitis is a type of uveitis, which is an inflammation of the uvea, the middle layer of the eye. Intermediate uveitis specifically involves inflammation in the vitreous, a gel-like substance in the middle of the eye and lead to the formation of inflammatory cells and debris in the vitreous. Symptoms include floaters, blurred vision, eye pain and redness. Diagnosis includes comprehensive...
-
Product Insights
NewPanuveitis – Drugs In Development, 2024
Empower your strategies with our Panuveitis – Drugs In Development, 2024 report and make more profitable business decisions. Panuveitis, or diffuse uveitis, is the inflammation of uveal components of the eye. It is caused by inflammation due to infections, immune-related inflammation, intraocular malignancies like retinoblastoma or iris melanoma, and traumas. Symptoms include pain, redness, watery discharge, photophobia, and edema. Diagnostics tests include blood tests, X-ray, and thorough eye examination, which includes slit-lamp exam, tonometry, and dilated eye exam. The treatment varies...
-
Product Insights
NewUveitis – Drugs In Development, 2024
Empower your strategies with our Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors...
-
Product Insights
Uveitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Uveitis Clinical Trials Market Report Overview The uveitis clinical trial market research report provides an overview of the uveitis clinical trials scenario. The report provides top-line data relating to the clinical trials on uveitis. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions North America,...